No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
| Autor: | Kenneth Sands, Laura E McLean, Jonathon D. Roach, Richard P. Wenzel, L. Hayley Burgess, Kimberly Korwek, Jonathan B. Perlin, Karla M Miller, Russell E. Poland, Edmund Jackson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty 030106 microbiology Population Azithromycin Article lcsh:Infectious and parasitic diseases 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Risk of mortality Humans lcsh:RC109-216 030212 general & internal medicine Young adult education education.field_of_study business.industry SARS-CoV-2 COVID-19 Retrospective cohort study Hydroxychloroquine General Medicine COVID-19 Drug Treatment Clinical trial Coronavirus Infectious Diseases Supportive psychotherapy business Coronavirus Infections medicine.drug |
| Zdroj: | International Journal of Infectious Diseases International Journal of Infectious Diseases, Vol 104, Iss, Pp 34-40 (2021) |
| ISSN: | 1201-9712 |
| DOI: | 10.1016/j.ijid.2020.12.060 |
| Popis: | Highlights • Hydroxychloroquine was proposed as a treatment for COVID-19 in the early pandemic. • Data from 1669 COVID-19 patients in the United States was analyzed. • Hydroxychloroquine was associated with an increased risk of mortality. Background The use of hydroxychloroquine (HCQ), with or without concurrent administration of azithromycin (AZM), for treatment of COVID-19 has received considerable attention. The purpose of this study was to determine whether HCQ administration is associated with improved mortality in COVID-19 patients. Methods We conducted a retrospective analysis of data collected during the care process for COVID-19 positive patients discharged from facilities affiliated with a large healthcare system in the United States as of April 27, 2020. Patients were categorized by treatment with HCQ (in addition to standard supportive therapy) or receipt of supportive therapy with no HCQ. Patient outcomes were evaluated for in-hospital mortality. Patient demographics and clinical characteristics were accounted for through a multivariable regression analysis. Results A total of 1669 patients were evaluated (no HCQ, n = 696; HCQ, n = 973). When adjusting for patient characteristics, receipt of AZM, and severity of disease at admission, there was no beneficial effect of receipt of HCQ on the risk of death. In this population, there was an 81% increase in the risk of mortality among patients who received HCQ at any time during their hospital stay versus no HCQ exposure (OR: 1.81, 95% CI: 1.20–2.77, p = 0.01). Conclusions In this retrospective analysis, we found that there was no benefit of administration of HCQ on mortality in COVID-19 patients. These results support recent changes to clinical trials that discourage the use of HCQ in COVID-19 patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|